[Tedizolid photo]
KEY POINTS
- Tedizolid (Sivextro) is an oxazolidinone antibiotic that works by binding to the 50S ribosomal subunit in bacteria, which inhibits protein synthesis
- In vitro time-kill studies show tedizolid as bacteriostatic against Enterococci, Staphylococci, and Streptococci
- Has activity versus MRSA
- Lacks Gram negative or anaerobic coverage
- FDA-approved in June 2014 for acute bacterial skin and skin structure infections
- Available oral and injectable
- IV and PO dose is the same as 200mg once per day
- Some people jokingly refer to this drug as once-a-day-zolid, because the other oxazolidinone, linezolid (Zyvox), is twice per day
- No renal or hepatic adjustments recommended
- IV and PO dose is the same as 200mg once per day
- Beware drug-drug interactions, especially with antipsychotic drugs
- Manufacturer recommends to consider alternative therapies if patients are neutropenic (neutrophil count below 1,000 cells/m3)
- Some of the side effects to beware include: headache, thrombocytopenia (low platelets), peripheral neuropathy, paresthesia, and visual impairment
- Brand only drug with no generic available, is of high cost as compared to other antibiotic that are generic
- Linezolid is available generic
RESOURCES
- Tedizolid Package Insert
- New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides (J Clin Micro 2016)
- Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic (Clin Infect Dis 2015)
- Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens (Drugs 2015)
[Photo source: www.Sivextro.com]
